EIGR - セラドン （Eiger BioPharmaceuticals Inc.）

During the last session, Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR)’s traded shares were 0.46 million, with the beta value of the company hitting 1.66. At the end of the trading day, the stock’s price was $7.25, reflecting an intraday loss of -3.97% or -$0.3. The 52-week high for the EIGR share is $10.02, that puts it down … As The Stock Rises By 39.69% Year-To-Date, Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR)’S Stock Continues To Progress In 2022 Read More »

https://www.investing.com/news/pro/eiger-biopharma-pt-lowered-to-48-at-btig-432SI-2887374

IVERIC bio ISEE +37%. First Wave BioPharma (FWBI) +32%. Eiger BioPharmaceuticals EIGR -29%. bioAffinity Technologies (BIAF) -22%.

The shares of commercial-stage biotech Eiger BioPharmaceuticals, Inc

According to Benzinga Pro data, during Q2, Eiger BioPharmaceuticals (NASDAQ: EIGR ) posted sales of $4.09 million. Earnings were up 3.35%, but Eiger BioPharmaceuticals still reported an overall loss of $21.88 million. In Q1, Eiger BioPharmaceuticals brought in $2.67 million in sales but lost $22.64 million in earnings. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of … Full story available on Benzinga.com

Eiger BioPharmaceuticals Inc (EIGR) shares closed 3.1% lower than its previous 52 week low, giving the company a market cap of $155M. The stock is currently down 11.6% year-to-date, down 59.5% over the past 12 months, and down 60.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 47.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -559.7% The company's stock price performance over the past 12 months lags the peer average by 295.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.5% above its 52 week low of $4.78, giving the company a market cap of $165M. The stock is currently down 6.0% year-to-date, down 58.2% over the past 12 months, and down 58.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 43.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -422.9% The company's stock price performance over the past 12 months lags the peer average by 313.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 0.6% above its 52 week low of $4.95, giving the company a market cap of $169M. The stock is currently down 4.0% year-to-date, down 60.4% over the past 12 months, and down 57.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 47.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -332.2% The company's stock price performance over the past 12 months lags the peer average by 399.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Eiger BioPharmaceuticals Inc (EIGR) shares closed today at 1.0% above its 52 week low of $5.07, giving the company a market cap of $175M. The stock is currently down 57.9% year-to-date, down 50.1% over the past 12 months, and down 52.8% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 14.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 291.2% The company's stock price performance over the past 12 months lags the peer average by 209.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

PALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious

Related Stocks: GOOG , INTU , PYPL , CDLX , FB , EIGR , RZLT , ADXN , LUXA , FLAC , SSAAU , GIGGU , MRAC , PTMN , GMIIU , FTOC , HEC , VGAC ,

Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis The post thoughts on these estimates, before EPS results? NASDAQ:KDMN, NASDAQ:EIGR, NASDAQ:SLRX, NASDAQ:FGBI appeared first on .

PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food

PALO ALTO, Calif., Aug. 3, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory,